Loading company…
Quris uses AI and miniaturized Patients-on-a-Chip to predict the safety and efficacy of drug candidates.
Founded in 2019 and based in Tel Aviv, Israel, Quris develops drug testing technology for pharmaceutical and biotechnology companies. Its Bio-AI Clinical Prediction Platform uses data from miniaturized Patients-on-a-Chip and machine learning to predict drug safety and efficacy in humans. In December 2022, Quris raised USD 9.000 mn in Seed funding led by SB Investment Advisers.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in